Skip to main content
CLOV
NASDAQ Finance

Clover Health Forecasts First-Ever GAAP Net Income Profitability in 2026 Amidst 53% Medicare Advantage Membership Growth

Analyse IA par Wiseek
Sentiment info
Positif
Importance info
9
Prix
$2.54
Cap. de marche
$1.312B
Plus bas 52 sem.
$2.12
Plus haut 52 sem.
$4.87
Market data snapshot near publication time

summarizeResume

Clover Health's announcement of expected full-year GAAP Net Income profitability for 2026 marks a critical turning point for the company, signaling a significant improvement in its financial trajectory. This positive outlook is underpinned by robust operational performance, including a substantial 53% year-over-year growth in Medicare Advantage membership. The company's strategic focus on core markets, strong member retention, and improved cohort economics, combined with a 4.0 Stars rating for its PPO plans and favorable CMS rate updates, suggests a sustainable path to profitability. This development could lead to a material re-evaluation of the company's investment thesis, shifting focus from growth at all costs to profitable expansion.


check_boxEvenements cles

  • Forecasts First-Ever GAAP Net Income Profitability

    Clover Health expects to achieve full-year GAAP Net Income profitability for the first time in 2026, indicating a significant financial milestone and improved operational efficiency.

  • Strong Medicare Advantage Membership Growth

    The company reported a 53% year-over-year increase in Medicare Advantage (MA) membership during the Annual Election Period (AEP), reaching approximately 153,000 members as of January 1, 2026.

  • Improved Cohort Economics and Quality Ratings

    Profitability is supported by strong returning member retention (>95%), a 4.0 Stars rating for its PPO plans for payment year 2026, favorable CMS rate updates, and continued SG&A leverage.

  • Industry-Leading Clinical Quality

    Over 97% of Clover's MA membership is in its flagship PPO plan, which is ranked #1 nationally on core HEDIS quality measures for the second consecutive year.


auto_awesomeAnalyse

Clover Health's announcement of expected full-year GAAP Net Income profitability for 2026 marks a critical turning point for the company, signaling a significant improvement in its financial trajectory. This positive outlook is underpinned by robust operational performance, including a substantial 53% year-over-year growth in Medicare Advantage membership. The company's strategic focus on core markets, strong member retention, and improved cohort economics, combined with a 4.0 Stars rating for its PPO plans and favorable CMS rate updates, suggests a sustainable path to profitability. This development could lead to a material re-evaluation of the company's investment thesis, shifting focus from growth at all costs to profitable expansion.

Au moment de ce dépôt, CLOV s'échangeait à 2,54 $ sur NASDAQ dans le secteur Finance, pour une capitalisation boursière d'environ 1,3 Md $. La fourchette de cours sur 52 semaines allait de 2,12 $ à 4,87 $. Ce dépôt a été évalué avec un sentiment de marché positif et un score d'importance de 9 sur 10.

descriptionVoir le depot SEC principal

show_chartGraphique des prix

Partager cet article

Copied!

feed CLOV - Dernieres analyses

CLOV
Apr 28, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
CLOV
Apr 01, 2026, 8:32 AM EDT
Filing Type: 8-K
Importance Score:
7
CLOV
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CLOV
Mar 10, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
8
CLOV
Mar 10, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
CLOV
Mar 06, 2026, 9:06 AM EST
Filing Type: 8-K/A
Importance Score:
8
CLOV
Feb 27, 2026, 8:08 AM EST
Filing Type: 10-K
Importance Score:
8
CLOV
Feb 26, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
9
CLOV
Jan 14, 2026, 8:32 AM EST
Filing Type: 8-K
Importance Score:
9
CLOV
Jan 09, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
7